Compounds and methods for enhancing erythropoiesis

Abstract

Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (I) indicated below, in which R is a glucosyl group. In addition to having an erythropoiesis effect, the compound of the formula (1) is effective in enhancing erythropoietin formation, and increasing kidney function and expression of hepatocyte growth factor. The method includes the step of administering an effective amount of the compound of the formula (I) to a subject in need thereof and thereby results in an enhancement of erythropoiesis.

1 . A method for enhancing erythropoietin formation in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R is a glycosyl group. 
     
     
         2 . The method of  claim 1 , wherein the glycosyl group is at least one selected from the group consisting of dihydroxyacetone, glucose, galactose, glyceraldehydes, threose, xylose, mannose, ribose, ribulose, xylulose, tagatose, psicose (allulose), fructose, sorbose, rhamnose, erythrose, erythrulose, arabinose, lyxose, allose, altrose, gulose, idose and talose, and any combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the compound of the formula (I) is administering to a tissue selected from the group consisting of bone marrow, a liver tissue and a kidney tissue, and any combinations thereof. 
     
     
         4 . A method for treating a disease and/or disorder in a subject that would benefit from erythropoietin treatment comprising the step of administering to the subject an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R is a glycosyl group. 
     
     
         5 . The method of  claim 4 , wherein the disease is at least one selected from anemia, a renal failure, and erythropoiesis deficiency-related diseases. 
     
     
         6 . The method of  claim 4 , wherein the disorder would benefit from an erythropoietin-related protective effect. 
     
     
         7 . The method of  claim 6 , wherein the erythropoietin-related protective effect is at least one selected from neuroprotection, cardiovascular protection, renoprotective effect, and protections from tissue ischemia and ischemia/reperfusion injury. 
     
     
         8 . A method for enhancing erythropoiesis in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R is a glycosyl group. 
     
     
         9 . The method of  claim 8 , wherein the glycosyl group is at least one selected from the group consisting of dihydroxyacetone, glucose, galactose, glyceraldehydes, threose, xylose, mannose, ribose, ribulose, xylulose, tagatose, psicose (allulose), fructose, sorbose, rhamnose, erythrose, erythrulose, arabinose, lyxose, allose, altrose, gulose, idose and talose, and any combinations thereof. 
     
     
         10 . A method for enhancing kidney function in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R is a glycosyl group. 
     
     
         11 . The method of  claim 10 , wherein the glycosyl group is at least one selected from the group consisting of dihydroxyacetone, glucose, galactose, glyceraldehydes, threose, xylose, mannose, ribose, ribulose, xylulose, tagatose, psicose (allulose), fructose, sorbose, rhamnose, erythrose, erythrulose, arabinose, lyxose, allose, altrose, gulose, idose and talose, and any combinations thereof. 
     
     
         12 . A method for enhancing the expression of hepatocyte growth factor in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R is a glycosyl group. 
     
     
         13 . The method of  claim 12 , wherein the glycosyl group is at least one selected from the group consisting of dihydroxyacetone, glucose, galactose, glyceraldehydes, threose, xylose, mannose, ribose, ribulose, xylulose, tagatose, psicose (allulose), fructose, sorbose, rhamnose, erythrose, erythrulose, arabinose, lyxose, allose, altrose, gulose, idose and talose, and any combinations thereof. 
     
     
         14 . A method for treating a disease and/or disorder in a subject that would benefit from hepatocyte growth factor treatment comprising the step of administering to the subject an effective amount of the compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R is a glycosyl group. 
     
     
         15 . The method of  claim 14 , wherein the glycosyl group is at least one selected from the group consisting of dihydroxyacetone, glucose, galactose, glyceraldehydes, threose, xylose, mannose, ribose, ribulose, xylilose, tagatose, psicose (allulose), fructose, sorbose, rhamnose, erythrose, erythrulose, arabinose, lyxose, allose, altrose, gulose, idose and talose, and any combinations thereof. 
     
     
         16 . The method of  claim 14 , wherein the disease and/or disorder is at least one selected from the group consisting of a liver disease, a kidney disease, a lung disease, a cardiovascular disease, a digestive disease, a neuronal disease, a bone disease, a joint disease, a muscular disease, a skin disease, crush syndrome, allergic inflammation, and any combinations thereof.